Skip to content

January 2026

Altered states of consciousness

What January 2026's 20 new studies found, synthesized from the papers below. All Altered states of consciousness research →

The synthesis

Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Altered states of consciousness, non-ordinary states, altered consciousness, ASC, then ranked by relevance.

Research in January 2026 found that ayahuasca enhances functional connectivity in social brain networks (third visual pathway and mirror neuron systems) and reduces depressive symptoms for up to 180 days when combined with psychotherapeutic support. The intensity of altered states from psychedelics is influenced by a combination of pharmacological, individual, and contextual factors, with spiritual/therapeutic intentions and higher doses producing stronger effects. However, ibogaine carries a rare but serious risk of cardiac complications, and the field lacks standardized assessment methods for VR-induced altered states.

Confidence in the evidence

Moderate
  • Multiple studies (n=12, n=280, n=804) provide converging evidence on ayahuasca's neural and clinical effects, but sample sizes are moderate and designs are observational or crossover rather than large RCTs.
  • The micro-phenomenological DMT study (n=23) and the VR review provide detailed qualitative and methodological insights but are limited by small samples or lack of standardization.
  • The ibogaine safety review is based on case reports and observational data, highlighting a known risk but without controlled trials to quantify incidence.
  • Overall, the evidence is consistent in direction but limited by small samples, lack of blinding, and variability in measurement tools across studies.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Ayahuasca (0.8 mg/kg DMT) significantly increased right pSTS connectivity and directed modulation from visual and mirror-neuron regions, with positive correlations to perspective-taking and improved social relationships at one-week follow-up.

crossover fMRI study Sample size: 12

Intensity of altered states was significantly predicted by spiritual/therapeutic intention, substance type (dissociative and serotonergic psychedelics > entactogens), higher dose, age, and gender.

retrospective naturalistic survey Sample size: 804

Ibogaine presents a rare but clinically significant risk of QTc prolongation and ventricular arrhythmias, even at therapeutic doses and in individuals without pre-existing cardiac conditions.

review

Ritualistic ayahuasca use combined with psychotherapeutic support led to significant reductions in depressive symptoms (MADRS) sustained for up to 180 days, though individual responses varied.

longitudinal observational study Sample size: 280

VR-induced altered states can be systematically evaluated through multimodal techniques, but significant methodological inconsistencies and lack of standardization in experimental designs and measurement tools were identified.

systematic review

Immersion under DMT follows a structured continuum from subtle to gross forms, with perceived presences emerging only after multisensory integration and 3D spatial characteristics develop.

micro-phenomenological study Sample size: 23

Points of agreement

  • Ayahuasca and DMT produce measurable changes in brain connectivity and subjective experience, with effects linked to social cognition and therapeutic outcomes.
  • The intensity of altered states is modulated by dose, intention, and individual factors such as age and gender.
  • Psychedelic-assisted therapy shows promise for depression and substance use disorders when combined with psychotherapeutic support.

Conflicts

  • No direct conflicts among the studies; however, the ibogaine safety review highlights a risk that contrasts with the generally positive therapeutic findings for other psychedelics.
  • The VR review notes a lack of standardization, which may conflict with the goal of replicable assessment across studies.

Gaps

  • Durability of effects beyond 180 days for ayahuasca therapy is not established.
  • Blinding and placebo controls are lacking in most studies, limiting causal inference.
  • Sample sizes are small for neuroimaging studies (n=12, n=23) and observational designs are prone to bias.
  • Standardized assessment tools for VR-induced altered states are missing.
  • Cardiac safety data for ibogaine are based on case reports rather than controlled trials.
  • The role of CYP2D6 genotyping in ibogaine safety is suggested but not empirically tested in the provided studies.
Browse these studies in the library